Department of Translational Research, Western University of Health Sciences, Pomona, California, USA.
Terasaki Institute for Biomedical Innovation (TIBI), Los Angeles, California, USA.
Tissue Eng Part B Rev. 2024 Feb;30(1):1-14. doi: 10.1089/ten.TEB.2023.0049. Epub 2023 Jul 4.
Myocardial infarction results in the significant loss of cardiomyocytes (CMs) due to the ischemic injury following coronary occlusion leading to impaired contractility, fibrosis, and ultimately heart failure. Stem cell therapy emerged as a promising regenerative strategy to replenish the otherwise terminally differentiated CM to restore cardiac function. Multiple strategies have been applied to successfully differentiate diverse stem cell populations into CM-like phenotypes characterized by the expression status of signature biomarkers and observable spontaneous contractions. This article discusses the current understanding and applications of various stem cell phenotypes to drive the differentiation machinery toward CM-like lineage. Impact Statement Ischemic heart disease (IHD) extensively affects a large proportion of the population worldwide. Unfortunately, current treatments for IHD are insufficient to restore cardiac effectiveness and functionality. A growing field in regenerative cardiology explores the potential for stem cell therapy following cardiovascular ischemic episodes. The thorough understanding regarding the potential and shortcomings of translational approaches to drive versatile stem cells to cardiomyocyte lineage paves the way for multiple opportunities for next-generation cardiac management.
心肌梗死导致心肌细胞(CMs)大量丢失,这是由于冠状动脉阻塞后的缺血损伤导致收缩功能受损、纤维化,最终导致心力衰竭。干细胞治疗作为一种有前途的再生策略,可补充终末分化的 CM,以恢复心脏功能。已经应用多种策略成功地将多种干细胞群体分化为 CM 样表型,其特征是标志性生物标志物的表达状态和可观察到的自发性收缩。本文讨论了各种干细胞表型的当前理解和应用,以推动向 CM 样谱系分化的机制。
影响说明
缺血性心脏病(IHD)广泛影响着全球很大一部分人群。不幸的是,目前治疗 IHD 的方法不足以恢复心脏的有效性和功能。再生心脏病学领域的一个研究热点是探索在心血管缺血事件后进行干细胞治疗的潜力。深入了解将多功能干细胞推向心肌细胞谱系的转化方法的潜力和局限性,为下一代心脏管理开辟了多种机会。